Global Psoriasis Drugs Market Size, Forecast, and Trend Highlights Over 2025-2037
Psoriasis Drugs Market size was valued at USD 21.6 billion in 2024 and is likely to cross USD 76.3 billion by 2037, registering more than 11.1% CAGR during the forecast period, i.e., 2025-2037. In 2025, the industry size of the psoriasis drugs is evaluated at USD 24 billion.
According to a study published by Frontiers in February 2024, the number of people with psoriasis surpassed 125.0 million, identifying a heightening occurrence among the age group of 30-39 till 2030. Another 2024 Journal of Clinical Medicine of Kazakhstan observed a higher prevalence of this condition in Western countries such as Norway, France, Portugal, and the U.S., and peak onset at 30-39 and 60-69 years. These figures signify the frequent incidence and severity of this disease among older adults. On the other hand, the WHO reported that the population of people aged 60 and over across the world is projected to increase to 2.1 billion by 2050. It showcases a continuous enlargement of the patient pool, driving demand in the market.
As this disease becomes a serious public health issue, authorities and institutions around the globe are proactively spreading knowledge about the risk factors and available treatments. Their efforts to increase the understanding of its characteristics and medicinal response are further promoting wide adoption in the market. These cohorts have introduced innovative and more effective management methods with greater recovery rates and lesser side effects. In addition, the introduction of AI and machine learning (ML) modules is helping dermatologists predict the intensity and progression of the condition, procuring better outcomes. On this note, an observational study was published by the NLM in September 2024, where ML showcased notable accuracy in determining the extent of the disease in 90.0% of the cases.
Psoriasis Drugs Sector: Growth Drivers and Challenges
Growth Drivers
- Exponential growth in biologics prescription: With the power of technological advancements in early detection and therapeutic development, biologics has come out to be the most effective solution. In this regard, a 2021 NLM article mentioned over 11 highly efficient FDA-approved biologic options. Similarly, in 2022, a systematic review from NLM on the short-term efficacy (10–16 weeks) of biologics presented 94.6% and 91.9% response rates among patients with 75.0% and 90.0% psoriasis area and severity index (PASI) reduction. This testifies to the continuously growing territory of these medicines in the market, contributing to a notable proportion of the profit margin.
- Rigorous R&D activities in designing therapies: In search of solutions with fewer adverse reactions, researchers are establishing the importance of long-term R&D cohorts in psoriasis management. Subsequently, as dermatologists tend to prescribe more precise medicines to reduce side effects and recurrence, the market is gaining traction. The improved and faster results from new therapeutics are further influencing dedicated organizations to engage in more exploration projects, extending business opportunities. For instance, in December 2024, Takeda revealed the potential of its six phase III clinical programs, including Zasocitinib in treating psoriasis, in generating revenue up to USD 20.0 billion by 2025.
Challenges
- Frequent & severe side effects of medications: Despite the growing developments in the psoriasis drugs market, the medicines might cause serious adverse reactions, such as high blood pressure, liver damage, cardiovascular dysfunction, and kidney damage. This might prevent consumers and dermatologists from adopting and prescribing it. However, continuous clinical research and studies have found solutions to mitigate this issue through the application of companion drugs.
Psoriasis Drugs Market: Key Insights
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2037 |
|
CAGR |
11.1% |
|
Base Year Market Size (2024) |
USD 21.6 billion |
|
Forecast Year Market Size (2037) |
USD 76.3 billion |
|
Regional Scope |
|
Psoriasis Drugs Segmentation
Drug Class (Corticosteroids, TNF Alpha Inhibitors, PDE4 Inhibitors, Interleukin Inhibitors, Others)
In terms of drug class, the TNF alpha inhibitors (TNFi) segment is expected to hold the largest share in the psoriasis drugs market over the assessed timeline. Clinical evidence demonstrating higher efficacy of this subtype in managing inflammation for patients with psoriatic arthritis is indicating the segment’s proprietorship over other drug classes. On this note, a comparative analysis between TNF alpha inhibitors and placebo, determined by evaluating results from 25 distinguished studies in various regions, was published by Cochrane in February 2025. It highlighted 35.9% and 25.8% higher clinical improvement and disease control within 12 and 24 weeks, respectively, among responders using TNFi. This drug was also found to be better than placebo in maintaining quality of life with more 3.2 points.
Route of Administration (Oral, Parenteral, Topical)
Based on the route of administration, the parenteral segment is predicted to generate greater revenue in the psoriasis drugs market by the end of 2037. This method of drug infusion is highly desired and used worldwide for treating moderate-to-severe cases, owing to the enhanced solubility, distribution, and localization of regimens in the body. For instance, in October 2023, UCB attained FDA approval for marketing BIMZELX (bimekizumab-bkzx) injections for moderate to severe plaque psoriasis in adults. It delivers fast, complete, and lasting skin clearance in candidates for systemic therapy or phototherapy. In addition, the introduction of advanced delivery systems such as nanotechnology and molecular formation of associated injectables are revolutionizing their therapeutic efficacy, making them more preferable.
Our in-depth analysis of the global psoriasis drugs market includes the following segments:
|
Drug Class |
|
|
Route of Administration |
|
|
Distribution Channel |
|
Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.
Customize this ReportPsoriasis Drugs Industry - Regional Synopsis
North American Market Forecast
Geographically, North America is anticipated to hold the largest share of 38.9% in the psoriasis drugs market throughout the analysed timeframe. The rising prevalence of psoriasis is a major factor contributing to this region’s dominance. According to the National Psoriasis Foundation, the population of U.S. habitats with this skin condition crossed 8.0 million in 2022, and 30.0% of this volume developed psoriatic arthritis (PsA). Simultaneously, the annual all-cause healthcare costs in the U.S. were determined to be USD 11,062.0 and USD 29,742.0 for each of the psoriasis and PsA patients in 2021: NLM. Moreover, various government initiatives supporting the adoption of innovative drugs, coupled with the presence of developed healthcare infrastructure, are some other drivers in this sector.
The U.S. is presenting a favourable environment for global leaders in the market with a supportive regulatory framework, large consumer base, and well-established healthcare industry. The country is home to several research-based biopharma pioneers, such as Amgen, Eli Lilly and Company, AbbVie, Johnson & Johnson, Bristol Myers Squibb, and others. For instance, in August 2024, Amgen announced the commercial launch of its Otezla (apremilast) in the U.S. market for pediatric psoriasis candidates. This is an indication of the nationwide presence of a profitable landscape, attracting more participants.
APAC Market Forecast
Asia Pacific is predicted to grow at a steady pace in the psoriasis drugs market during the discussed period between 2025 and 2037. The spreading awareness about the condition and development of healthcare infrastructure in the region is stimulating this growth. Governing bodies in developing countries, such as Japan, China, and India, are supporting this promotion with accelerated approvals, subsidiary policies, and financial investments. For instance, in May 2024, the Central Drugs Standard Control Organisation (CSDCO) provided clearance to Boehringer Ingelheim for marketing its SPEVIGO (spesolimab) injection in India. This first-in-class treatment is indicated to treat generalized pustular psoriasis flares in adults. Such events are further attracting more companies to invest in this landscape.
Japan is augmenting the market with a strong emphasis on precision medicine and technologically advanced clinical trials. To recover from the drug-loss state, the country is cultivating new distribution channels and extended production capacities in various medical disciplines, including dermatology. This is fostering a progressive atmosphere for this sector, helping both domestic and foreign leaders garner lucrative profit. For instance, in January 2022, UCB gained approval from the Ministry of Health, Labour and Welfare (MHLW) for marketing BIMZELX (bimekizumab) to treat plaque & generalized pustular psoriasis and psoriatic erythroderma in Japan.
Companies Dominating the Psoriasis Drugs Landscape
- Pfizer Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Novartis AG
- GlaxoSmithKline plc.
- Johnson & Johnson Services, Inc.
- Amgen Inc.
- Celgene Corporation
- AbbVie Inc.
- Eli Lilly and Company
- AstraZeneca
- Biocon
- Bristol Myers Squibb
- Organon & Co.
The market is evolving with the advancements in R&D methods and treatment prognosis. This has helped key players in this sector draft optimum safety profiles for their product line and attain maximum regulatory compliance in a shorter time, accelerating the pace of globalization. It is attracting more biopharmaceutical producers to participate in this cohort, increasing availability in this field. For instance, in September 2024, Arcutis Biotherapeutics received a supplemental new drug application (sNDA) acceptance from the FDA for its ZORYVE (roflumilast) foam 0.3%. This phosphodiesterase-4 inhibitor is intended to treat both adults and adolescents (aged 12 and over) with scalp and body psoriasis with a once-daily dose. Such inspiring innovators are:
In the News
- In March 2025, Johnson & Johnson released promising results from the phase 3 clinical trial on icotrokinra, demonstrating a Psoriasis Area and Severity Index (PASI)90 response in 50.0% of the candidates. This oral pill surpassed the efficacy of an injectable biologic, ustekinumab, in treating plaque psoriasis.
- In February 2025, Bristol Myers Squibb shared new five-year results from the POETYK PSO long-term extension (LTE) trial on Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque psoriasis. The study showcased a consistency in the safety profile of this therapeutic.
Author Credits: Radhika Pawar
- Report ID: 2144
- Published Date: Apr 28, 2025
- Report Format: PDF, PPT
